Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mepolizumab in COPD With Eosinophilic Bronchitis: A Randomized Clinical Trial.

Next Previous
X
Search
Trial Profile

Mepolizumab in COPD With Eosinophilic Bronchitis: A Randomized Clinical Trial.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Mar 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use

    • Most Recent Events

    • 01 Mar 2017 Results published in the European Respiratory Journal
    • 07 Mar 2016 Primary endpoint has been met. (Eosinophil count (Decrease in sputum eosinophil percentage.)), as per an abstract presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 07 Mar 2016 Results presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top